仑伐替尼治疗放射性碘难治性分化型甲状腺癌及与生存相关的候选生物标志物:韩国多中心研究
这项韩国多中心研究纳入43例放射性碘难治性分化型甲状腺癌患者,接受仑伐替尼一线或索拉非尼后二线治疗,中位无进展生存期为21.8个月,疾病控制率97.7%,中位总生存期未达到;甲状腺球蛋白倍增时间和肿瘤生长斜率与无进展生存期相关。
要点
- 仑伐替尼治疗放射性碘难治性分化型甲状腺癌的中位无进展生存期为21.8个月,疾病控制率97.7%。
- 因不良事件将仑伐替尼中位起始剂量20 mg降至中位可持续剂量10 mg后,疗效未见减弱。
- 甲状腺球蛋白倍增时间和肿瘤生长斜率与无进展生存期相关。
核心结论
- 因不良事件而降低仑伐替尼剂量并未削弱其在放射性碘难治性分化型甲状腺癌患者中的明显疗效,持续使用低剂量仑伐替尼且严重不良事件发生率低可能有助于获得良好结局。
- 甲状腺球蛋白倍增时间和肿瘤生长斜率可协助预测这些患者的结局。
研究设计与样本
- 多中心研究,纳入43例放射性碘难治性分化型甲状腺癌患者,接受仑伐替尼作为一线治疗或索拉非尼后的二线治疗。
主要发现
- 患者接受仑伐替尼治疗的中位时间为14个月,其中32例既往接受过索拉非尼治疗。
- 从仑伐替尼起始至末次删失或死亡的中位随访时间为16个月。
- 中位起始剂量20 mg因患者不良事件降至中位可持续剂量10 mg。
- 中位无进展生存期为21.8个月,中位总生存期未达到,疾病控制率为97.7%,首次客观缓解出现在3.8个月。
- 无进展生存期与既往索拉非尼治疗、转移部位或可持续剂量无显著关联;仑伐替尼起始前(TGSpre,p=0.003)和起始后(TGSpost,p=0.036)的肿瘤生长斜率与无进展生存期相关;靶病灶最大直径之和(p=0.043)和甲状腺球蛋白倍增时间(p=0.024)与无进展生存期相关,但仑伐替尼治疗前(TVDTpre,p=0.923)或治疗后(TVDTpost,p=0.966)计算的肿瘤体积倍增时间未影响无进展生存期。
关键数值与推荐
- 24例患者(55.8%)停用仑伐替尼:6例因治疗相关不良事件,18例因疾病进展或体能状态差。
- 所有患者均报告任何级别的不良事件,23.2%的患者报告3-4级不良事件。
- 最常见的不良事件为疲乏或乏力。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Lenvatinib, an oral multikinase inhibitor, is the latest addition to the treatment options for radioactive iodine (RAI)-refractory progressive differentiated thyroid carcinoma (DTC). This study investigated the efficacy of lenvatinib in real-world practice and prognostic biomarkers of survival. Methods: This multicenter study included 43 patients receiving lenvatinib as first-line or second-line treatment after sorafenib for RAI-refractory DTC. Progression-free survival (PFS) was evaluated according to various clinical factors including thyroglobulin doubling time (TgDT), tumor volume DT (TVDT), and tumor growth slope (TGS; slope of tumor change rate). Results: Patients were treated with lenvatinib for a median of 14 months; 32 were previously treated with sorafenib. The median follow-up from lenvatinib initiation to the last censoring or death was 16 months. The median starting dose of 20 mg was reduced to a median sustainable dose of 10 mg in accordance with patient adverse events (AEs). The median PFS was 21.8 months; the median overall survival was not reached. The disease control rate was 97.7%, with the first objective response at 3.8 months. PFS was not significantly associated with previous sorafenib treatment, metastatic sites, or sustainable dose. TGS measured before (TGSpre, p = 0.003) and after (TGSpost, p = 0.036) the initiation of lenvatinib was associated with PFS. The sum of the largest diameters of target lesions (p = 0.043) and TgDT (p = 0.024) were associated with PFS, but TVDT calculated before (TVDTpre, p = 0.923) or after (TVDTpost, p = 0.966) lenvatinib treatment did not impact PFS. Lenvatinib was withdrawn in 24 patients (55.8%): in 6 patients because of treatment-induced AEs and in 18 patients because of disease progression or poor performance status. AEs of any grade were reported in all patients, and grade 3-4 AEs in 23.2% of the patients. The most frequent AE was fatigue or asthenia. Conclusions: Our results indicate that reduced doses of lenvatinib triggered by emergent AEs did not abrogate its apparent efficacy in patients with RAI-refractory DTCs. Rather, the sustained use of reduced doses of lenvatinib with a low rate of severe AEs may have contributed to the favorable outcomes. TgDT and TGS can assist in predicting the outcomes in these patients.
引用
- Song E, Kim M, Kim EY, et al. Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea. Thyroid. 2020. PMID: 31910091. doi:10.1089/thy.2019.0476
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。